| Autor: |
van Adelsberg, J., Philip, G., Pedinoff, A.J., Meltzer, E.O., Ratner, P.H., Menten, J., Reiss, T.F. |
| Předmět: |
|
| Zdroj: |
Allergy; Dec2003, Vol. 58 Issue 12, p1268-1276, 9p |
| Abstrakt: |
Proinflammatory mediators such as the cysteinyl leukotrienes are important in the pathophysiology of allergic rhinitis. This study evaluated the efficacy and tolerability of montelukast, a cysteinyl leukotriene receptor antagonist, given once daily in the morning for treatment of seasonal (fall) allergic rhinitis for 4 weeks. This was a randomized, double-blind trial with a placebo run-in and a 4-week treatment period. Patients ( n = 1079) with a history of allergic rhinitis and a positive skin test to seasonal pollen allergens were assigned to placebo, montelukast 10 mg, or loratadine 10 mg. Symptoms were assessed with a daily diary. Montelukast was more effective than placebo in improving scores for the primary endpoint of daytime nasal symptoms ( P = 0.003) and the secondary endpoints of night-time, composite, and daytime eye symptoms, patient's and physician's global evaluations of allergic rhinitis, and rhinoconjunctivitis quality-of-life ( P ≤ 0.006). The positive control loratadine also improved scores for the primary endpoint ( P ≤ 0.001) and the majority of the secondary endpoints ( P < 0.03). When analyzed by week, the treatment effect of montelukast was more persistent than loratadine over all 4 weeks of treatment. Montelukast provided effective relief of seasonal allergic rhinitis symptoms when given once daily in the morning, showed significant and sustained improvement in symptoms of allergic rhinitis over 4 weeks of treatment, and was well-tolerated. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text